Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2016, specifically dated January 19, 2016. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
On January 19, 2016, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent titled "A3 Adenosine Receptor Allosteric Modulators." This represents a significant milestone in the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard incorporation of the press release. The primary focus is the regulatory approval of the patent application.
Investor Verification Checklist
- Verify the scope and claims of the "A3 Adenosine Receptor Allosteric Modulators" patent via the attached press release (Exhibit 99.1).
- Confirm the status of the patent issuance in the USPTO database.
- Review the company's most recent Form 20-F for the latest financial position, as this 6-K contains no financial data.